Learn about Benign Prostatic Hyperplasia with Urinary Retention (BPH with Urinary Retention). This resource provides information on diagnosis, clinical documentation, and medical coding for prostate enlargement with urinary retention. Find details relevant to healthcare professionals for accurate and efficient documentation and coding practices.
Also known as
Diseases of male genital organs
Covers conditions affecting the male reproductive system, including BPH.
Other symptoms and signs involving the urinary system
Includes urinary retention, a key symptom of BPH.
Diseases of the genitourinary system
Broader category encompassing both reproductive and urinary diseases.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the urinary retention due to BPH?
When to use each related code
| Description |
|---|
| Enlarged prostate with inability to empty bladder |
| Enlarged prostate without blockage |
| Sudden inability to urinate |
Coding BPH with retention requires specifying acute or chronic retention (e.g., N40.1, N40.0). Unspecified retention lacks coding specificity.
Distinguishing BPH (N40.0/N40.1) from other prostate obstructions impacting coding and may require additional documentation.
Documenting related conditions like urinary tract infections or hydronephrosis improves coding accuracy and reflects patient complexity.
Q: What are the best evidence-based practices for managing acute urinary retention in patients with Benign Prostatic Hyperplasia (BPH)?
A: Managing acute urinary retention (AUR) in BPH patients requires prompt intervention to relieve the obstruction and restore bladder function. Initial management involves catheterization, either urethral or suprapubic, to drain the bladder. Consider implementing a trial without catheter (TWOC) after a period of catheterization and alpha-blocker therapy. For patients with persistent or recurrent AUR, surgical interventions such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), or laser prostatectomy may be necessary. Explore how different surgical approaches compare in terms of efficacy, complications, and long-term outcomes. Choice of treatment should be individualized based on factors like prostate size, patient comorbidities, and patient preferences. Learn more about the AUA guidelines for the management of BPH and lower urinary tract symptoms.
Q: How can I differentiate between BPH with Urinary Retention and other causes of urinary retention in male patients, such as prostate cancer or neurogenic bladder?
A: Differentiating BPH with urinary retention from other causes requires a thorough clinical evaluation. A digital rectal examination (DRE) helps assess prostate size, consistency, and nodularity. While BPH typically presents with a smooth, enlarged prostate, prostate cancer may present with hard, irregular nodules. Urinalysis and urine culture can rule out infection. Serum prostate-specific antigen (PSA) testing may be indicated, but it's crucial to remember that elevated PSA can occur in both BPH and prostate cancer. Consider incorporating urodynamic studies to evaluate bladder function and identify potential neurogenic bladder. Imaging studies, such as ultrasound or MRI, can provide detailed information about the prostate and urinary tract. Explore how different diagnostic modalities can help differentiate BPH with urinary retention from other conditions, especially when clinical findings are ambiguous.
Patient presents with lower urinary tract symptoms (LUTS) consistent with benign prostatic hyperplasia (BPH) complicated by acute urinary retention. The patient reports a history of increasing urinary frequency, urgency, nocturia, weak stream, hesitancy, and straining to void. He now experiences a painful inability to urinate despite a sensation of bladder fullness. Digital rectal examination (DRE) reveals an enlarged, smooth, non-tender prostate. Post-void residual (PVR) urine volume measured via bladder scan is significantly elevated, confirming urinary retention. Differential diagnosis includes bladder outlet obstruction, neurogenic bladder, and prostate cancer. Initial management includes urethral catheterization for immediate bladder decompression. Urinalysis and serum creatinine ordered to assess for infection and renal function. Treatment plan includes consideration of alpha-blockers, 5-alpha reductase inhibitors, and possible surgical intervention such as transurethral resection of the prostate (TURP) or minimally invasive procedures depending on prostate size, symptom severity, and patient preference. Patient education provided regarding BPH, urinary retention, medication options, and potential surgical risks and benefits. Follow-up scheduled to monitor treatment response and assess for complications.